Vision for 2031
Mochida Pharmaceutical Group's long-term vision is to "Grow as a unique life and healthcare group whose raison d'etre is recognized internationally and which meets medical and healthcare needs."
In May 2022, to achieve sustainable growth by overcoming a business environment that is expected to become increasingly severe in the future, we have given shape to our long-term vision and developed the "Vision for 2031" that the Group aims to realize in 2031.
Amid the diversification and sophistication of medical care, such as addressing intractable and rare diseases that have been difficult to treat with conventional small molecules and antibody drugs alone, we aim to take on the challenge of addressing unmet medical and health needs by incorporating new drug discovery modalities that are expected to grow in the future.
In addition to the current mainstay pharmaceutical and healthcare businesses, we are working to work to position the biomaterials business as one of the pillars of the next generation.
Efforts toward 2031
Pharmaceutical business
- To incorporate new drug discovery modalities, such as cells, nucleic acids, and genes, to enhance our drug discovery pipeline and maintain the position as a core business
- Among them, to position regenerative medicine products as one of our focus areas and give priority to projects using mesenchymal stem cells
- To launch products from our pipeline that incorporate new drug discovery modalities, including regenerative medicine products, by FY2031
Biomaterials business
- To promote each project based on alginate, which is expected to have various medical applications, and work for an early launch and business expansion. Also, to promote development with a view to global expansion.
Healthcare business
- To focus on developing high-performance, value-added dermatological skin care products through communications with physicians, pharmacists, and nurses etc
- To steadily expand the scale of our business by improving our business structure via the investment of sales resources, etc., focusing on new areas, and introducing new and renewed products
Global expansion
- To expand into overseas markets by offering a lineup of distinctive products that meet the needs in each business segment
- To launch highly purified EPA drugs in Vietnam, China, the U.S., and other countries, subsequently to Thailand
- Also, to promote the development of medical devices in our biomaterials business and regenerative medicine products in our pharmaceuticals business, which we aim to launch in the future, with a view to global expansion
Scale of business targeted for 2031
We aim to achieve sales of approximately 40 billion yen, including product fields such as the biomaterials business products and regenerative medicine products in the pharmaceutical business, which are positioned as one of the pillars of the next generation.
With these new businesses as growth drivers, we aim to develop our business to achieve total net sales of 140 billion yen and an operating margin of 15%.